SimBioSys Gets FDA Clearance for AI Breast Cancer Recurrence Tool
Oct 15, 2026
Biotech
ScreenPoint Medical's Transpara AI Chosen for $16M Breast Cancer Screening Trial
Sep 24, 2025
ScreenPoint Medical's Transpara AI has been selected for the PRISM Trial, a $16 million study in the U.S. to evaluate AI's role in breast cancer screening.
ScreenPoint Medical has announced that its Transpara breast imaging AI solution will be used in the PRISM Trial, a significant randomized controlled trial in the United States. Announced in a press release, the trial is funded by a $16 million award from the Patient-Centered Outcomes Research Institute (PCORI) and aims to assess the effectiveness of AI in breast cancer screening.
The PRISM Trial, led by UCLA and UC Davis, will explore whether AI can assist radiologists in detecting breast cancer earlier, improving mammography accuracy, and reducing unnecessary patient callbacks. The study will involve hundreds of thousands of mammograms interpreted at leading academic medical centers, including UCLA, UC Davis, and others.
ScreenPoint Medical's Transpara Detection software will be integrated into the clinical workflow using the Aidoc aiOS platform, supporting the trial's objectives to enhance early breast cancer detection and improve patient-centered care systems.
We hope you enjoyed this article
Consider subscribing to one of our newsletters like AI Funding Brief, Life AI Weekly or Daily AI Brief.
Also, consider following us on social media:
More from Funding
Oct 16 RapidCanvas Raises $29 Million to Expand Enterprise AI Platform Oct 16 KBRA Rated Anthropic BB+ Before $35 Billion Chip Financing Oct 16 Goodweek Raises $12 Million for AI Management Platform Oct 16 Intuit Agrees to Acquire AI Billing Startup Sequence for Reported $200 Million Oct 16 Matters Raises $5 Million to Build AI Consumer BankMore from Life Sciences
Oct 16 Study Tests Smartphone AI for Children's Lung Sounds Oct 16 Manhattan Physician Invests in RunPractice Oct 16 Attilio appoints Buck Institute CEO Eric Verdin as cochairman Oct 16 Aignostics launches HETA Clinical for pathology workflows Oct 16 Specialty1 Partners Invests in AI for Dental Practice OperationsFree newsletter
Life AI Weekly
Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.
Industry analysis
2025 Global Business Services Agenda: Gen AI Takes Center Stage
The Hackett Group
This industry analysis by The Hackett Group explores the transformative impact of generative artificial intelligence (Gen AI) on global business services (GBS) in 2025. The study highlights the shift from exploration to acceleration of Gen AI initiatives, with 89% of executives advancing these projects to improve customer satisfaction, innovate products, and reduce costs. The report also discusses the challenges and strategies for successful Gen AI adoption, emphasizing the need for a technology-enabled operating model and the importance of reskilling the workforce.
Read moreYou may also like
TRI Launches TRIAL.OS for Clinical Trial Management
Oct 13, 2026
Healthcare
MediSights Reports Study Using AI Agents for Myeloma Market Research
Sep 16, 2026
Marketing AI
LUNGevity Awards $2 Million for Lung Nodule Risk Studies
Sep 29, 2026
Healthcare
HOPPR Brings Radiology Foundation Models to CARPL.ai
Oct 07, 2026
Healthcare
Brainomix and Pulmonary Fibrosis Foundation Partner on AI Lung Imaging Research
Oct 14, 2026
Healthcare
Free, six days a week
Daily AI Brief: the AI news that matters, in your inbox.